Kevin Ali - 05 May 2025 Form 4 Insider Report for Organon & Co. (OGN)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: OGN
Reported as of: 05 May 2025
Net transaction value: +$299,370
SEC form: 4
Accepted by SEC: 06 May 2025, 13:58:08 UTC
Prior SEC filing: 02 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Tarnetta V. Jones, as Attorney-in-Fact for Kevin Ali

Key filing fact

Kevin Ali filed Form 4 for Organon & Co. (OGN) on 06 May 2025.

Key facts

This page summarizes Kevin Ali's Form 4 filing for Organon & Co. (OGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 May 2025, 13:58.

Change

Previous filing in this sequence was filed on 02 Apr 2025.
Current net transaction value: +$299,370.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001859698 Primary reporting owner

Ali Kevin

Relationship: Chief Executive Officer, Director
Address: C/O ORGANON & CO., 30 HUDSON STREET, FLOOR 33, JERSEY CITY
Signature: /s/ Tarnetta V. Jones, as Attorney-in-Fact for Kevin Ali
Signature date: 06 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OGN transaction

Common Stock

Purchase

Transaction value: $299,370
Shares: +34,000
Change %: +14%
Price: $8.80
Shares after: 282,731
Date: 05 May 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.765 to $8.850, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.